Every Form 4 that Boston Scientific Corporation (BSX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
Boston Scientific (BSX) executive EVP & Group President, Cardiology, reported two bona fide gifts of common stock. The filings show a Code G transaction for 690 shares on 11/12/2025 at $0.0000, followed by a Code G transaction for 9,610 shares on 11/14/2025 at $0.0000.
After these transactions, the reporting person held 168,042 shares directly. An additional 5,234 shares are listed as held indirectly by child, with a stated disclaimer of beneficial ownership.
Boston Scientific (BSX) director reported an open‑market sale of 12,891 common shares on November 6, 2025 at a weighted average price of $98.2839, executed under a pre‑established Rule 10b5-1 trading plan adopted on July 25, 2025.
The filing notes sales occurred across a price range of $97.89 to $98.65. Following the transaction, the reporting person beneficially owns 24,134 shares directly.
Boston Scientific (BSX) reported an insider transaction by its EVP & Group President, Cardiology. On 11/03/2025, the officer exercised 50,000 stock options at $26.15 and sold a total of 50,000 common shares in three trades at $100.7481 (3,600 shares), $99.7607 (16,928), and $99.1414 (29,472), pursuant to a pre-established Rule 10b5-1 plan adopted on February 27, 2025.
Following these transactions, the officer directly owns 178,342 shares and indirectly holds 5,234 shares through a child.
Boston Scientific (BSX) Chairman, President & CEO and Director Michael F. Mahoney filed a Form 4 reporting gifts of common stock involving trusts. On 10/29/2025, Code G entries recorded 88,197 shares (A) and 73,996 shares (A) at $0.0000, with indirect ownership noted as “By Trust.”
On 10/30/2025, a Code G entry recorded 149,992 shares (D) at $0.0000, with indirect ownership noted as “By Trust.” The footnotes state the transactions involved gifts by The Michael F. Mahoney 2 Year Qualified Annuity Trust – 2023 and – 2024, and a gift by the reporting person to The Michael F. Mahoney Term Irrevocable Trust – 2025, each administered by an independent trustee.
Boston Scientific (BSX) reported an insider Form 4 that corrects a previously reported sale. On October 29, 2025, a transaction coded J recorded the addition of 12,891 shares at $0, reflecting that an aggregate sale of the same amount disclosed the prior day was made in error and was rescinded through the broker’s error account. The filing states these sales are deemed to have never occurred.
Following the correction, the reporting person directly beneficially owns 37,025 shares of Boston Scientific common stock.
Boston Scientific (BSX): Director stock sale reported on Form 4. A company director sold 9,990 shares of common stock on 10/27/2025 at a weighted average price of $101.1312 and 2,901 shares on 10/28/2025 at a weighted average price of $102.2402. The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.
Following these sales, the reporting person directly beneficially owns 24,134 shares. Weighted average prices reflect multiple trades within the disclosed ranges, and full trade breakdowns are available upon request.
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported option activity and open-market sales on 10/01/2025. The filing shows a grant of a stock option to purchase 50,000 shares with an exercise price of $26.15; the option vests in four equal annual installments and the reported exercisable/expiration schedule lists an expiration of 12/01/2027. On the same date the reporting person sold 8,245 shares at a weighted average price of $98.9063 and 41,755 shares at a weighted average price of $98.3797, totaling 50,000 shares sold. The transactions were effected under a pre-established Rule 10b5-1 trading plan adopted 02/27/2025. The report disclaims beneficial ownership of 5,234 shares held by the reporting person’s child. The Form 4 was signed by an attorney-in-fact on 10/01/2025.